State Street Corp trimmed its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 12.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,413,827 shares of the company's stock after selling 495,459 shares during the quarter. State Street Corp owned 4.80% of Altimmune worth $20,961,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its position in shares of Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock worth $3,791,000 after purchasing an additional 335,444 shares in the last quarter. Bellevue Group AG boosted its holdings in Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company's stock worth $5,303,000 after buying an additional 263,660 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Altimmune during the second quarter worth about $689,000. Exchange Traded Concepts LLC increased its holdings in Altimmune by 74.4% in the third quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company's stock valued at $1,331,000 after buying an additional 92,498 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Altimmune by 28.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company's stock valued at $1,621,000 after acquiring an additional 54,154 shares during the period. 78.05% of the stock is owned by hedge funds and other institutional investors.
Altimmune Trading Down 2.7 %
Shares of NASDAQ ALT traded down $0.21 during midday trading on Tuesday, reaching $7.55. 1,339,650 shares of the stock were exchanged, compared to its average volume of 3,821,083. The stock has a 50 day moving average price of $7.96 and a 200-day moving average price of $7.11. The company has a market capitalization of $536.99 million, a P/E ratio of -4.87 and a beta of 0.15. Altimmune, Inc. has a 52-week low of $5.28 and a 52-week high of $14.84.
Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter. During the same quarter last year, the firm posted ($0.39) earnings per share. On average, analysts forecast that Altimmune, Inc. will post -1.36 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on ALT shares. UBS Group began coverage on Altimmune in a report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Altimmune presently has an average rating of "Moderate Buy" and a consensus target price of $20.00.
View Our Latest Research Report on ALT
Altimmune Company Profile
(
Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Further Reading
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.